PBYI Earnings Date: Nov 5, 2026 (Estimated) — Puma Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PBYI's next earnings date?
Puma Biotechnology, Inc. (PBYI) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.09 on revenue of $57.5M.
How did PBYI do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Puma Biotechnology, Inc. posted EPS of $0.19 versus the $0.04 estimate, a beat of 171.4%. Revenue was $53.6M against a $53.0M estimate. The stock's 1-day post-earnings move was +9.7%.
How much does PBYI stock move after earnings?
PBYI beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.3% (up or down) in the day after earnings.
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.04 | 0.19 | +171.43% | $53.6M | ✅ Beat | +9.73% | +7.27% | +17.61% |
| 2026-05-07 | Q1 2026 | -0.14 | -0.04 | +71.43% | $44.8M | ✅ Beat | +3.17% | -0.96% | -5.65% |
| 2026-02-26 | Q4 2025 | 0.21 | 0.29 | +38.10% | $75.5M | ✅ Beat | -25.00% | -18.03% | -20.00% |
| 2025-11-06 | Q3 2025 | 0.08 | 0.21 | +162.50% | $54.5M | ✅ Beat | +22.24% | +1.02% | +10.20% |
| 2025-08-07 | Q2 2025 | 0.07 | 0.15 | +114.29% | $49.2M | ✅ Beat | +12.16% | +61.70% | +38.60% |
| 2025-02-27 | Q4 2024 | 0.14 | 0.43 | +207.14% | $59.1M | ✅ Beat | +19.73% | +20.90% | +5.02% |
| 2024-11-07 | Q3 2024 | 0.35 | 0.45 | +28.57% | $80.5M | ✅ Beat | -4.95% | -1.32% | -3.63% |
| 2024-08-01 | Q2 2024 | -0.10 | -0.05 | +50.00% | $47.1M | ✅ Beat | +9.43% | +9.43% | -28.57% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $56.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 94.8% | $53.6M | +8.9% | $94.7M | $43.1M | $49.2M | $51.9M |
| Royalty | 5.2% | $2.9M | -9.4% | $8.2M | $2.9M | $3.2M | $2.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.